The Report “PharmaPoint: Hemophilia A and B – Argentina Drug Forecast and Market Analysis to 2022″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “PharmaPoint: Hemophilia A and B – Argentina Drug Forecast and Market Analysis to 2022″ in subject line and your contact details to purchase this report or get your questions answered.
The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.
Argentina ranks fourth among pharmaceutical markets in Latin America. According to primary research, the majority of Argentine hemophilia patients have access to recombinant FVIII and RIX products through private insurance plans or through the national social security program. However, the national insurance program only covers on-demand treatment and plasma-derived concentrates.
Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=141247 .
Scope
• Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in Argentina including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in Argentina from 2012-2022.
• Analysis of the impact of key events as well the drivers and restraints affecting Argentina Hemophilia A and B market.
Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-hemophilia-a-and-b-argentina-drug-forecast-and-market-analysis-to-2022-market-report.html . Read more on “PharmaPoint: Hemophilia A and B – Argentina Drug Forecast and Market Analysis to 2022” report below.
Reasons to buy
• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2012-2022 in Argentina
Buy a copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=141247 .
